Virtual Library

Start Your Search

Ole Christian Lindgjærde



Author of

  • +

    P3.03 - Biology (Not CME Accredited Session) (ID 969)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.03-26 - Tumor Immune Microenvironment in NSCLC is Predictive of Prognosis After Surgery (ID 13802)

      12:00 - 13:30  |  Author(s): Ole Christian Lindgjærde

      • Abstract

      Background

      To investigate the tumor microenvironment in NSCLC and try to understand more about how, and why, it differs in histological and expression subtypes of NSCLC .

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Samples were collected from 399 patients who underwent surgery for stage I-IV NSCLC at Oslo university hospital 2006-16. Gene expression was assessed by using Agilent microarray on samples from adenocarcinomas (n=184) and squamous cell carcinomas (n=183) separately. RNA sequencing was performed of 32 samples. Of these 53 % (n=17) were adenocarcinomas (AD) and 47 % (n=15) were squamous cell carcinomas (SCC). Xcell(1) was used to find the proportion of different cells in the tumor microenvironment and to calculate an immunescore. All samples were assigned a gene expression subtype by using previously described nearest centroid classifiers for AD and SCC respectively (2, 3)

      4c3880bb027f159e801041b1021e88e8 Result

      For AD we found significant differences in progression free survival (PFS) between the three expression subtypes with better prognosis for TRU versus non-TRU and worse for PP versus non-PP, adjusted for stage. We found no differences in prognosis between SCC expression subtypes. Higher immune score was associated with better PFS in AD but not in SCC.

      8eea62084ca7e541d918e823422bd82e Conclusion

      The composition of both stromal and immune cells in the tumor microenvironment will be further investigated. Differential gene expression analysis will be preformed to better understand what differentiates immunologically active from immunologically silent tumors.

      1. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220.

      2. Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One. 2012;7(5):e36530.

      3. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res. 2010;16(19):4864-75.

      6f8b794f3246b0c1e1780bb4d4d5dc53